EP0574530A1 — Endothelin antagonists
Assigned to Research Corp Technologies Inc · Expires 1993-12-22 · 32y expired
What this patent protects
The invention relates to a compound comprising an endothelin antagonist polypeptide homologous to at least 40% of an active endothelin peptide, constitutive of Et-1, Et-2, Et-3, SC, SA and SB, of the formula (I), as well as its pharmaceutically acceptable salts.
USPTO Abstract
The invention relates to a compound comprising an endothelin antagonist polypeptide homologous to at least 40% of an active endothelin peptide, constitutive of Et-1, Et-2, Et-3, SC, SA and SB, of the formula (I), as well as its pharmaceutically acceptable salts.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.